Site menu

Search by ticker code:
Generic filters


Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Pro Medicus (ASX:PME) Share Price Rises On New US Contract Win

The Pro Medicus (ASX: PME) share price is up 3% after winning a new US-based long term contract.

Pro Medicus is a Melbourne-based software owner and developer, licensing products to large US hospitals and Australian radiology clinics. The company has offices in Richmond, Victoria, Berlin, Germany and in the United States.

Pro Medicus’ Latest Contract Win

It has signed a five year deal with the Ohio State University Wexler Medical Center (OSUWMC). Visage 7 will be implemented across all of OSUWMC’s radiology departments.

The contract is based on a transaction-based licensing model which will span seven hospitals and outpatient clinics as well as being integrated to OSUWMC’s electronic health record.

OSUWMC is a large organisation, employing approximately 30,000 staff, 1,700 physicians supporting 1,500 inpatient beds. It’s also the teaching hospital for the Ohio State University College of Medicine (OSUCOM).

The implementation will be in the second quarter of FY20 and complete in mid 2020.

Management said in an interview with Open Briefing that this contract is similar to its other North American contracts with minimums so there is upside in terms of normal volumes and anything else that is added in the future.

Pro Medicus has won a few large contracts over the past 12 months including one in Germany, an agreement with Partners Healthcare and an agreement with Duke Health.

In the interview Pro Medicus CEO Sam Hupert explained that the recently-awarded WA Governemnt contract worth $45 million wasn’t worth bidding on because the revenue to the supplier is only a fraction of the headline number and not worth the effort, instead it was better focusing elsewhere. Pro Medicus has decided not to bid on government contracts for that reason.

Mr Hupert explained that the announced North American contracts are the opposite – the numbers are baseline and 100% of the revenue goes to Pro Medicus.

Finally, Mr Hupert talked about how the company is working on a number of opportunities in the pipeline. Pro Medicus is seeing the network effect benefits of its implementation with Partners Healthcare.

[ls_content_block id=”19823″ para=”paragraphs”]

[ls_content_block id=”18380″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content